Princeton Medical Institute, a leading clinical research and evaluation center for patients with depression and memory problems including Alzheimer’s and normal age-associated memory impairment (AAMI), is enrolling interested patients in clinical trials.
This is a chance to participate in groundbreaking research for issues that are often misdiagnosed or go undiagnosed. Particularly in the elderly, depression can be hard to identify and can include apathy, memory issues, appetite problems, and unexpected aches and pains. Dr. Jeffrey Apter, a nationally renowned depression and Alzheimer’s specialist, runs these trials.
“There are many advantages to the patient who participates in our trials, which typically run three to six months: free treatment, tests, office visits, and trial medications,” said Dr. Apter. “In many cases, participating in a clinical trial means the patient may benefit from the drug up to five years before it’s ultimately approved.”
The Lundbeck Study is for geriatric depression. Candidates are those who are 65 years old or older who are depressed and/or taking an anti-depressant. The DART Neuroscience Study is for AAMI and is for those 50 years old or older who are experiencing general memory issues or problems.
“As we get older, memory issues and depression are common, but it’s hard to differentiate which causes which,” Dr. Apter added. “These studies help people improve the quality of their life. They offer some hope through medications that aren’t available on the market yet.”
Dr. Apter is the founder and president of Global Medical Institutes and is the lead principle investigator for Princeton Medical Institute. He has published more than 25 articles in the area of psychiatric research and has been a nationwide opinion leader in psychopharmacology for more than a decade. He is an attending physician at the University Medical Center of Princeton at Plainsboro and a research collaborator in the Department of Molecular Biology at Princeton University.
Princeton Medical Institute also offers ongoing Alzheimer’s studies. Dr. Apter emphasizes that clinical trials are a real service to the public good. Not only do they test drugs to prepare them to come to market, but there also is a high level of medical attention given to each participant, including a variety medical tests and office visits. Those interested should call 609-921-6050 to see if they qualify.
Princeton Medical Institute, Woodlands Professional Building, 256 Bunn Drive, Suite 6, Princeton. 609-921-6050, princetonmed1@gmail.com, or www.princetonmedicalinstitute.com.
